ID   EGI-1
AC   CVCL_1193
SY   Egi-1; EGI1
DR   CLO; CLO_0002895
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473571
DR   CCLE; EGI1_BILIARY_TRACT
DR   Cell_Model_Passport; SIDM01050
DR   ChEMBL-Cells; CHEMBL3308731
DR   ChEMBL-Targets; CHEMBL1075442
DR   Cosmic; 906853
DR   Cosmic; 927186
DR   Cosmic; 1373548
DR   Cosmic; 2674064
DR   Cosmic-CLP; 906853
DR   DepMap; ACH-001494
DR   DSMZ; ACC-385
DR   GDSC; 906853
DR   GEO; GSM1669758
DR   IARC_TP53; 21324
DR   LINCS_LDP; LCL-1787
DR   PharmacoDB; EGI1_327_2019
DR   Wikidata; Q54832088
RX   CelloPub=CLPUB00275;
RX   PubMed=20164919;
RX   PubMed=27231123;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=32899426;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: >45 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.79%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=77.61%; European, South=21.59% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; DepMap; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 11
ST   D16S539: 11,12,13 (DepMap)
ST   D16S539: 12,13 (Cosmic-CLP; DSMZ)
ST   D18S51: 14,16
ST   D21S11: 28,33.2
ST   D3S1358: 14,17
ST   D5S818: 13
ST   D7S820: 9,13
ST   D8S1179: 11,16
ST   FGA: 20,24,25
ST   Penta D: 7,9
ST   Penta E: 5,11
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 17,18,19 (DepMap)
ST   vWA: 17,19 (Cosmic-CLP; DSMZ)
DI   NCIt; C4436; Cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 29
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H.,
RA   Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510;
RA   Scherer D., Davila Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Bermejo J.L.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//